ThromboGenics NV announced that the FDA Dermatologic and Ophthalmic Drugs Advisory Committee has recommended that the FDA grant ocriplasmin approval...
The FDA has approved the dermal filler Bellafill. from Suneva Medical, for the treatment of Acne Scars. Bellafill represents a...
The German health technology appraisal institute, IQWiG, considers that Jetrea (ocriplasmin) from Thrombogenics, offers "major" and "considerable" benefits over standard...
The first article in this continuing medical education series reviews HS epidemiology, clinical presentation, and classification.
. This scholarly review focuses on the causes and pathogenetic mechanisms of HS and the potential therapeutic value of this knowledge.
Palisade Bio, Inc. announced the first patient has been dosed in its Phase III study evaluating LB 1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery.
Solta Medical has received FDA 510(k) clearance of its Fraxel Dual 1550/1927 laser system for the treatment of pigmented lesions...
Promore Pharma provides clarification regarding media data on previous studies with ensereptide (PXL 01) regarding skin scarring In a commentary on the publication of Promore Pharma's new strategy focusing on scars on the skin, the media has directed a historical review of research results published in 2012, where it was referred to that a study with ensereptide against scarring did not reach its primary goals.
Galderma has announced positive results from OSCAR, a phase IV trial, a multicenter, randomized, investigator-blinded, vehicle-controlled, intra-individual comparison study (right/left...
Hidradenitis suppurativa influences patients' lives in many ways.